Levetiracetam-induced rhabdomyolysis: Analysis of reports from the Food and Drug Administration's Adverse Event Reporting System database-Reference-Cited by-同舟云学术

Levetiracetam-induced rhabdomyolysis: Analysis of reports from the Food and Drug Administration's Adverse Event Reporting System database

Published:2017-09-30 Issue:6 Volume:56 Page:E176-E178
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle Nerve

Author:

Carnovale Carla¹,Gentili Marta¹,Antoniazzi Stefania²,Clementi Emilio³⁴^ORCID,Radice Sonia¹

Affiliation:

1. Department of Biomedical and Clinical Sciences, Clinical Pharmacology Unit, ASST Fatebenefratelli-Sacco University Hospital; University of Milan; Milan Italy

2. Scientific Direction, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Milan Italy

3. Department Biomedical and Clinical Sciences, Clinical Pharmacology Unit, CNR Institute of Neuroscience, Sacco University Hospital; University of Milan; Milan Italy

4. Scientific Institute, IRCCS E. Medea; Bosisio Parini LC Italy

Funder

Centre of Pharmacovigilance of Regione Lombardia

Italian Ministry of Health

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Clinical Neurology,Physiology

Reference9 articles.

1. Rhabdomyolysis associated with levetiracetam administration;Lorenzo;Muscle Nerve,2017

2. Rhabdomyolysis in a hospitalized 16-year-old boy: a rarely reported underlying cause;Singh;Case Rep Pediatr,2016

3. Acute rhabdomyolysis associated with levetiracetam therapy in a child;Incecik;Acta Neurol Belg,2016